UroToday.com
@urotoday
Followers
29K
Following
34K
Media
39K
Statuses
119K
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
Joined February 2009
Absolute lymphocyte count and neutrophil-to-lymphocyte ratios: Overlooked biomarkers in cancer treatment outcomes. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss research across multiple tumor types showing that patients maintaining ALC above 1,500 have
4
53
182
Papillary non-muscle invasive #BladderCancer treatment guidelines gap. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss expanding ANKTIVA® (NAI) use to include papillary-only BCG-unresponsive bladder cancer. 📊 82% bladder preservation at 36 months.🧬
5
48
177
Radical prostatectomy vs radiotherapy in high-risk #ProstateCancer: Emulated randomized comparison with individual patient data from two phase III randomized trials. - A new emulated RCT analysis finds that radiotherapy + long-term ADT results in lower distant metastasis rates
1
73
143
Recombinant BCG addressing #BladderCancer treatment shortages. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access
1
27
134
The role of community partnerships in advancing our understanding of #ProstateCancer disparities and improving patient outcomes. @SamWashUro @UCSFCancer & @yawnyame @UW joins @dr_coops @UCSF to discuss on UroToday >
0
11
77
#RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. @GiuliaMarvaso84 shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT + short-course hormonal therapy in oligorecurrent #PCa. Results show enhanced biochemical and clinical progression-free
2
34
70
#STORM trial examines elective nodal radiotherapy in treating #ProstateCancer recurrence. @piet_ost @ugent joins @zklaassen_md @GACancerCenter to discuss, emphasizing that ENRT offers longer disease-free periods and lower pelvic recurrence rates compared to SBRT. #WatchNow >
1
36
68
Potential cost savings based on the #MarkCuban #CostPlus Drug Company model. @RuchikaTalwarMD @VUMCurology joins @UroCancerMD @VUMC_Cancer to discuss the @JCO_ASCO publication looking at the @mcuban @costplusdrugs. #WatchNow > #HealthPolicy
10
13
63
#RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. @GiuliaMarvaso84 shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT + short-course hormonal therapy in oligorecurrent #PCa. Results show enhanced biochemical and clinical progression-free
0
44
67
Metastatic hormone-sensitive #ProstateCancer – So many randomized trials (nine), yet monotherapy treatment persists. Presented by @OncHahn @MDAndersonNews. #AUA25 written coverage by @RKSayyid @USC > @AmerUrological
0
28
67
#PSMAandBeyond2025: Overview of clinical trials of PSMA RLT in 2025. Presentation by @CalaisJeremie @UCLAHealth. Written coverage by @zklaassen_md @GACancerCenter > @PCFnews @PSMAconference
1
20
61
Rapid-Fire #Debate: Patient with high-risk #NMIBC - Is BCG still the best option in 2025? Yes, BCG is still king. Presentation by @GGiannarini. #EAU25 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb
0
18
60
Novel therapies for non-muscle invasive #BladderCancer: Expert Review. @DrFelixGuerrero @Urologia12 joins @UroDocAsh @MDAndersonNews to discuss this @EurUrolOncol review. Dr. Guerrero-Ramos presents an overview of emerging therapies across different risk categories of NMIBC,
0
31
60
PSA persistence after radical prostatectomy: Optimal treatment in the case of PSA persistence. Presentation by @profnickjames @ICR_London. #EAU24 written coverage by @RKSayyid @UofT on UroToday > @Uroweb
0
18
56
PACE-C trial results: SBRT vs moderate hypofractionation for high-risk #ProstateCancer. @zklaassen_md talks with @alison_tree on the latest results from the PACE-C trial. With 1,208 patients randomized, early findings show similar GU toxicity & slightly higher GI side effects for
0
19
59
#NIAGARA trial: Chemo + durvalumab improves survival in muscle-invasive #BladderCancer. @tompowles1 @QMBCI joins @shilpaonc @CleClinicMD to discuss the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in
2
19
57
Novel therapies for non-muscle invasive #BladderCancer: Expert Review. @DrFelixGuerrero @Urologia12 joins @UroDocAsh @MDAndersonNews to discuss this @EurUrolOncol review. Dr. Guerrero-Ramos presents an overview of emerging therapies across different risk categories of NMIBC,
2
26
59
Molecular subtypes in #UrothelialCarcinoma as predictors of response to immunotherapy. #ExpertCommentary @FaltasLab @WCMEnglanderIPM discusses work from @HabibHamidPhD et al. in @Cancer_Cell which characterized the molecular determinants of response and resistance to PD-L1
1
18
58
Risk stratification for a 3 cm small renal mass – à la carte treatment approaches: surveillance, partial nephrectomy, SBRT, and focal ablation. Presentation by @drphil_urology, @NNHarke, @_ShankarSiva, and @Dmitry_Enikeev. #EAU25 written coverage by @RKSayyid >
1
30
54
Unraveling the efficacy of PD-1/PDL-1 re-challenge in #KidneyCancer.@DrChoueiri @DanaFarber_GU joins @CaPsurvivorship @DanaFarber in this discussion of the #CONTACT03 study on UroToday. 🧬🎯 > @TheLancet @montypal @AlbigesL @tompowles1 @crisuarez08
0
17
55
The best sequence for M+ castrate-resistant #ProstateCancer in 2020. Presented by @AlisonBirtle @LancsHospitals. #EAU20 written coverage by @GoldbergHanan @UpstateNews on UroToday > @Uroweb
1
29
55
High-volume de novo metastatic hormone-sensitive #ProstateCancer: Local treatment matters. Presentation by Karim Fizazi, MD, PhD @GustaveRoussy. #EAU25 written coverage by @chavarriagaj @UofT > @Uroweb
1
25
54
Stereotactic ablative body radiotherapy for #KidneyCancer. Still experimental? Presentation by @_ShankarSiva @PeterMacCC. #ESOU22 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb
0
18
52
Neoadjuvant vs adjuvant strategies in locally advanced #BladderCancer. Neoadjuvant strategies presented by @AndreaNecchi @IstTumori. #EMUC20 written coverage by @WallisCJD @VUMChealth on UroToday > @myESMO @Uroweb @ESTRO_RT
0
23
53
#RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. @GiuliaMarvaso84 shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT + short-course hormonal therapy in oligorecurrent #PCa. Results show enhanced biochemical and clinical progression-free
0
23
54
Testosterone recovery after stopping ADT – who is at risk for long-term non-recovery? Presented by @PBlanchardMD @GustaveRoussy. #APCCC24 Written coverage by @zklaassen_md @GACancerCenter @mcg_urology. > @APCCC_Lugano
0
19
52
My algorithm for decision making in #mCRPC. Presentation by @ChrisSweens1. #EAU25 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb
2
27
53
Radiation therapy for small cell #BladderCancer. Presentation by @VedangMurthy @TataMemorial. #ASTRO24 written coverage by @zklaassen_md @GACancerCenter > @ASTRO_org
1
14
48
Novel therapies for non-muscle invasive #BladderCancer: Expert Review. @DrFelixGuerrero @Urologia12 joins @UroDocAsh @MDAndersonNews to discuss this @EurUrolOncol review. Dr. Guerrero-Ramos presents an overview of emerging therapies across different risk categories of NMIBC,
2
17
49
Metastasis-directed therapy improves outcomes in oligometastatic #ProstateCancer in #WOLVERINE study. @ChadTangMD @MDAndersonNews sits down with @l_ballas @CedarsSinai to discuss a meta-analysis of STOMP, ORIOLE, ARTO, EXTEND & COMET-SABR trials on oligometastatic
1
22
50
Management of Biochemical Recurrence after Radiation Therapy for Localized #ProstateCancer: Reirradiation, Brachytherapy and SBRT. Juanita Crook, MD. FRCPC @UBC on Salvage Reirradiation for Radio-Recurrent #ProstateCancer. 💡 Salvage Options:.✅ LDR Brachytherapy: 5-yr BCR-free
1
23
50
"Mapping Progress in Bladder Cancer" This rapidly evolving landscape is incredibly exciting. @UroDocAsh @MDAndersonNews expands on the progress in bladder cancer & an explosion of clinical trials expanding our options. Full article by .on UroToday now.
1
37
47
#RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. @GiuliaMarvaso84 shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT + short-course hormonal therapy in oligorecurrent #PCa. Results show enhanced biochemical and clinical progression-free
1
18
49
#WatchNow.Radium-223 + enzalutamide improves survival in #mCRPC: #PEACE-3 trial results. @RKSayyid @USC and @zklaassen_md @GACancerCenter join in this UroToday #JournalClub to discuss the resurgence of radium-223 in treating mCRPC >
2
27
49
Bridging evidence to practice: #BladderCancer therapy guidelines and global implementation. @apolo_andrea @theNCI and @UroDocAsh @MDAndersonNews discuss new standards in bladder cancer care, spotlighting the #EV302 and #CheckMate901 trials. Enfortumab vedotin + pembro now sets
0
16
47
T-cell engagers in #ProstateCancer treatment. @neerajaiims joins @CaPsurvivorship to discuss the rationale behind T-cell engagers, and their potential to bypass the limitations of prostate cancer's cold tumor microenvironment. Full video on UroToday >
1
13
46
VIRADS - Can we avoid TUR-B prior to radical cystectomy? Presentation by @VPanebiancoIT. #EMUC20 written coverage by @zklaassen_md @GACancerCenter on UroToday > @myESMO @ESTRO_RT @Uroweb
1
19
47
Different #BladderCancer Genotypes: New treatment options. #EAU20 presentation by @Roland3097 @unibern. Written coverage by @GoldbergHanan @UpstateNews on UroToday > @Uroweb
1
28
45
An update on #QUILT-3.032: Complete responses to N-803 + BCG therapy in BCG-unresponsive bladder carcinoma in situ (CIS) with or without Ta/T1 papillary disease. Presented by @UroCancerMD @VUMCurology. #AUA25 written coverage by @RKSayyid @USC >
1
14
48
How MRI changed the #BladderCancer pathway: #NewEvidence. Presentation by @VPanebiancoIT @SapienzaRoma. #ESOU21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb
0
16
44
There is no role for radical cystectomy in cT0 after neoadjuvant chemotherapy. Presentation by @amassonlecomte @HopSaintLouis. #EAU21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb
0
15
44
State of the Art Lecture: Synchronous vs metachronous #mHSPC: What makes the difference? Presentation by @ChrisSweens1 @DanaFarber. #EAU22 written coverage by @rksayyid @UofTUrology > @Uroweb
0
18
45
#EAU25 #Debate: De novo low-volume metastatic hormone-sensitive #ProstateCancer: Total eradication is the way to go. Presentation by @AlbertoBossial @GustaveRoussy. Written coverage by @chavarriagaj @UofT > @Uroweb #EAU2025
0
17
45
The top 10 reasons why BCG (as a monotherapy) will cease to exist. @ctleeuro @OSU_Urology joins @zklaassen_md @GACancerCenter, outlining various challenges with BCG therapy, including administration difficulties, treatment intensity, and worldwide shortages, while highlighting
2
10
44
This systematic review identifies key genomic risk factors for #UrethralStricture, revealing downregulation of CXCR3 and NOS2, and upregulation of TGFB1, UPK3A, and CTGF in affected tissues. Notably, PI3K and TGF-β1/SMAD pathways are linked to these changes. These insights could
2
11
43
ESMO 2024 Quick Take Insights: Prostate Cancer.- #ARANOTE: Darolutamide + ADT shows significant rPFS benefits in mHSPC, offering a new treatment without docetaxel. - #PEACE3Study: Radium-223 + enzalutamide in mCRPC enhances rPFS & OS when used with bone protection in patients
0
17
44
TODAY UroToday is celebrating 15 years online! Stay tuned for how we are celebrating!! @CaPsurvivorship @charlesryanmd @UroDocAsh @PhillipKooMD @Daniel_J_George @montypal @DrDianeNewman ( @PennUrology ) @PelvicMedicine @wandering_gu @uretericbud @PGrivasMDPhD @jaimelandmanuci
3
10
43
Decipher® in #mHSPC: Guiding risk assessment and treatment intensification. @AttardLab @ucl joins @Prof_Nick_James @ICR_London discussing findings from the #STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. #FullVideo on UroToday >
0
12
41
How to identify aggressive variant prostate cancer? Presented by Himisha Beltran, MD, @DanaFarber @harvardmed. #APCCC24 Written coverage by @RKSayyid @UofTUrology @ihpmeuoft. > @APCCC_Lugano
0
17
43
SunRISe-4: TAR-200 + cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with #MIBC ineligible for or refuse neoadjuvant platinum-based chemotherapy. Presented by @spsutkaMD @fredhutch. @ASCO #GU23 written coverage by @WallisCJD @UofT >
2
6
43
Enfortumab vedotin and pembrolizumab demonstrate durable responses in advanced #BladderCancer. @tompowles1 @QMBCI joins @UroDocAsh @MDAndersonNews sharing 26-month data on enfortumab vedotin + pembrolizumab in advanced urothelial cancer. 💥 50% risk reduction in progression &
1
14
43
Pelvic lymph node dissection in #ProstateCancer: Update of the limited vs. extended randomized clinical trial. Presented by @TouijerKarim @MSKCancerCenter. #EAU24 written coverage by @rksayyid, MD, MSc @UofT > @Uroweb
1
15
43
#STORM trial examines elective nodal radiotherapy in treating #ProstateCancer recurrence. @piet_ost @ugent joins @zklaassen_md @GACancerCenter to discuss, emphasizing that ENRT offers longer disease-free periods and lower pelvic recurrence rates compared to SBRT. #WatchNow >
0
20
42
Is digital rectal examination for the definition of local T-stage still appropriate in the time of MRI and next-generation imaging? Presentation by @declangmurphy @PeterMacCC. #APCCC24 written coverage by @RKSayyid @UofT > @APCCC_Lugano
1
20
43
The role of radiotherapy for patients with node-positive locally advanced #ProstateCancer. Presentation by @PCaParker @royalmarsdenNHS. #ESMO21 written coverage by @WallisCJD @UofT on UroToday > @myESMO
0
24
42
#MoonRISe-1: Phase 3 study of #TAR210, an erdafitinib intravesical delivery system, vs intravesical chemotherapy in patients with IR #NMIBC with susceptible FGFR alterations. Presentation by @UrogerliMD @MoffittNews. #AUA24 coverage by @zklaassen_md >
1
16
42
Molecular sub-staging of #BladderCancer: Is it really useful? Presentation by @pcvblack @VanProstateCtr. #EMUC20 written coverage by @WallisCJD @VUMChealth on UroToday > @myESMO @Uroweb @ESTRO_RT
1
16
40
The triangle offense: Harnessing NK cells, T-cells, and memory cells in #BladderCancer. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss this groundbreaking approach for bladder cancer but potentially for other cancers as well >
8
10
39
Unveiling the treatment landscape for #mCRPC in #NorthAmerica! What's the current state of #ProstateCancer care? Read this insightful review by @RKSayyid @UofT & @zklaassen_md @GACancerCenter on UroToday >
0
17
41
#RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. @GiuliaMarvaso84 shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT + short-course hormonal therapy in oligorecurrent #PCa. Results show enhanced biochemical and clinical progression-free
1
16
41
New Video! .Cardiovascular risks of ARSIs in #ProstateCancer: Meta-analysis findings. @RKSayyid @USC & @zklaassen_md @GACancerCenter emphasize the importance of comprehensive cardiovascular assessment before initiating ARSI treatment > @JAMAOnc
1
23
41
Enfortumab vedotin and pembrolizumab demonstrate durable responses in advanced #BladderCancer. @tompowles1 @QMBCI joins @UroDocAsh @MDAndersonNews sharing 26-month data on enfortumab vedotin + pembrolizumab in advanced urothelial cancer. 💥 50% risk reduction in progression &
0
11
39
Avelumab combined with stereotactic ablative body radiotherapy in #mCRPC: The phase 2 ICE-PAC clinical trial. #BeyondTheAbstract with @EdmondMKwan, @SpainLavinia, Angelyn Anton, @DrBenTran, @_ShankarSiva, and @AzadOncology on UroToday > @EUplatinum
3
13
36
Optimal first-line therapy in metastatic disease. Presentation by @MattGalsky @TischCancer. #EMUC20 written coverage by @WallisCJD @VUMChealth on UroToday > @myESMO @ESTRO_RT @Uroweb
0
14
40
#NIAGARA trial: Chemo + durvalumab improves survival in muscle-invasive #BladderCancer. @tompowles1 @QMBCI joins @shilpaonc @CleClinicMD to discuss the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in
2
13
39
Metastasis-directed therapy for oligorecurrent #ProstateCancer: a pooled analysis of prospective trials. Presented by @piet_ost @ugent. #EUA21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb @declangmurphy @r_glicksman @matthewdeek
1
20
38
#PSMAandBeyond2025: Terbium-161 (161Tb) in #ProstateCancer.@DrMHofman @PeterMacCC presents data on 161Tb-PSMA, a promising alternative to 177Lu!. 🔬 #VIOLET trial: First-in-human study shows 161Tb delivers 40% more radiation per unit than 177Lu.📉 Preclinical data suggests better
0
12
39
PARP Inhibitor resistance mechanisms in #ProstateCancer. Professor Johann De Bono @ICR_London discusses a decade of research on #PARPi resistance!. Findings from the #TOPARP trials show BRCA2/PALB2 tumors restore DNA repair via POLθ, driving resistance. Could PARP + POLθ
2
17
39
This study compares two cutting-edge PET radiotracers, 68Ga-NeoB and 68Ga-PSMA-R2, in detecting biochemically recurrent prostate cancer. Results show 68Ga-NeoB outperforms in detecting metastases at lower PSA levels, offering a promising alternative for molecular imaging and
1
16
34
Addressing cognitive decline in #BladderCancer patients through prehab and rehab. @spsutkaMD @fredhutch joins @zklaassen_md @GACancerCenter to share how treatments can impact cognitive function, affecting up to 1/3 of patients and highlights strategies like brain training,
2
10
38
#NIAGARA trial: Chemo + durvalumab improves survival in muscle-invasive #BladderCancer. @tompowles1 @QMBCI joins @shilpaonc @CleClinicMD to discuss the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in
1
11
38
2024 @NCCN Guidelines update: metastatic castration-resistant #ProstateCancer treatment. @RKSayyid & @zklaassen_md discuss current management and key updates emphasizing the importance of confirming castrate status and proper staging >
1
12
36
Head-to-head comparison of micro-ultrasound, mpMRI, and PSMA PET/CT with a wholemount histopathology as gold standard in the detection and T staging of #ProstateCancer. Presentation by @wayne_brisbane @UCLAHealth. #GU25 written coverage by @chavarriagaj @UofT >
0
15
38
What is changing in advanced #ProstateCancer? #EverydayUrology #Journal article. @WallisCJD and @zklaassen_md "review the evidence underpinning recent changes in the management of patients with mCRPC, mCSPC, and nmCRPC." #ReadNow on UroToday >
0
22
38
Oligometastatic vs oligoprogressive #RCC treatment strategies. @ChadTangMD @MDAndersonNews and @l_ballas @CedarsSinai dive into the role of SBRT for #mRCC. 🔹 Oligometastatic RCC: SBRT can delay the need for systemic therapy. 🔹 Oligoprogressive RCC: SBRT may extend the benefit
1
12
37
Treatment options for de novo metastatic hormone-sensitive #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter in a case-based discussion Dr. Agarwal emphasizes the importance of treatment intensification beyond ADT monotherapy, which remains
1
16
38
#ProstateCancer case studies: Localized, salvage radiotherapy/BCR, #mHSPC, and #mCRPC. A panel discussion led by @DrRanaMcKay along with @TDorffOnc, @AmarUKishan, Arash Kalebasty, MD, and @jgong15. #SoCalGU24 written coverage by @zklaassen_md >
0
18
37
Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic #ProstateCancer (#EXTEND): A multicenter, randomized phase II trial. Presented by @ChadTangMD @MDAndersonNews. #ASTRO22 written coverage by @rksayyid > @ASTRO_org
0
8
37
Metastatic #ProstateCancer: Possible synergies between radioligand and systemic treatment in M1 prostate cancer? Future perspectives. Presentation by @ProfKHerrmann @unidue. #EAU22 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb
0
13
36
Evolving Landscape for Frontline Treatment in Clear Cell Metastatic Renal Cell Carcinoma. @PGrivasMDPhD @fredhutch is joined by @DrChoueiri @DanaFarber, and @montypal @cityofhope highlighting the #CLEAR study in this conversation on UroToday > @UW
0
8
37
Darolutamide, enzalutamide, and apalutamide for #nmCRPC patients in the #UnitedStates #DEAR: Comparative real-world evidence. Presentation by @zklaassen_md @GACancerCenter. #SESAUA2024 written coverage by @RKSayyid @UofT > @SES_AUA #SESAUA24
0
16
37
🚨 Promising alternative to BCG for #NMIBC! Drs. @SHPatelMD1 & @MaxKates @brady_urology sit down with @UroCancerMD @VUMCurology to discuss phase II trial results: 100% complete response at 3 months & 92% at 12 months with gemcitabine + docetaxel. Key takeaways: combination
0
16
37
PCWG4 and SPARC - Including How to Define Progression on PSMA PET Imaging. Presentation by Michael Morris, MD @MSKCancerCenter. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter > @APCCC_Lugano #APCCC25
0
17
37
5-Year survival outcomes in cisplatin-ineligible patients from #EV103. @DrRosenbergMSK @MSKCancerCenter joins @CaPsurvivorship @DanaFarber discuss the 5-year results from EV-103 Cohort A in advanced urothelial cancer. 🌟 Over 40% alive at 5 yrs (vs ~3% w/ chemo), showcasing
2
14
36
Oligometastatic vs oligoprogressive #RCC treatment strategies. @ChadTangMD @MDAndersonNews and @l_ballas @CedarsSinai dive into the role of SBRT for #mRCC. 🔹 Oligometastatic RCC: SBRT can delay the need for systemic therapy. 🔹 Oligoprogressive RCC: SBRT may extend the benefit
1
13
36
🔬 #PSMAandBeyond2025 #Keynote: @DrMHofman @PeterMacCC on combination therapy in #ProstateCancer. 🚀 Trials show #LuPSMA + combo strategies improve outcomes:.📈 ENZA-p: LuPSMA + enzalutamide → ⬆️ PSA PFS (13 vs. 7.8 mo, HR 0.43).🎯 LuPARP: LuPSMA + olaparib → 65% PSA50, 78% ORR
0
17
36
The triangle offense: Harnessing NK cells, T-cells, and memory cells in #BladderCancer. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss this groundbreaking approach for bladder cancer but potentially for other cancers as well >
1
5
36
Salvage radiotherapy options for biochemical recurrence after local treatment. Presentation by @a_dalpra @SylvesterCancer. #GU24 written coverage by @zklaassen_md @GACancerCenter on UroToday > @ASCO
0
16
35
Complete vs partial TURBT for muscle-invasive #BladderCancer treatment. @UroLiedberg, @UroMoschini & @BenjaminPradere join @UroDocAsh in a discussion on the extent of transurethral resection of bladder tumor needed in #MIBC. They debate the value of complete resection when
1
6
36
PARP Inhibitor resistance mechanisms in #ProstateCancer. Professor Johann De Bono @ICR_London discusses a decade of research on #PARPi resistance!. Findings from the #TOPARP trials show BRCA2/PALB2 tumors restore DNA repair via POLθ, driving resistance. Could PARP + POLθ
0
16
36
#STORM trial examines elective nodal radiotherapy in treating #ProstateCancer recurrence. @piet_ost @ugent joins @zklaassen_md @GACancerCenter to discuss, emphasizing that ENRT offers longer disease-free periods and lower pelvic recurrence rates compared to SBRT. #WatchNow >
1
13
35